In alignment with declines in hepatic steatosis, we also found that 17α-E2 treatment robustly downregulated hepatic SCD1 protein in male WT, but not ERβKO, mice (Fig. 5A,B), which is congruent with our prior report46. Here, SCD is linked to fatty liver disease.